Abstract
Reducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance, and secondary malignancy. Retroperitoneal lymph node dissection (RPLND) is a standard treatment for nonseminomatous germ cell tumors (NSGCT) that has minimal long-term morbidity. Given the efficacy of RPLND in management of NSGCT, interest has developed in this surgery as a front-line treatment for seminoma with isolated lymph node metastasis to the retroperitoneum. Four retrospective studies have shown promising results when surgery is performed for seminomas with low-volume retroperitoneal metastases. To better determine if RPLND can be recommended as a primary treatment option, two prospective clinical trials (SEMS and PRIMETEST) are underway. This review will examine the literature, discuss the benefits/limitations of RPLND, and compare the methodologies of the two ongoing clinical trials.
References
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·G E HanksJ Owen
Aug 1, 1997·Scandinavian Journal of Urology and Nephrology·N Warszawski, M Schmücking
Apr 11, 2003·The Journal of Urology·Axel HeidenreichUNKNOWN German Testicular Cancer Study Group
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunar K ZagarsSara S Strom
Nov 18, 2006·International Urology and Nephrology·Zaza Mezvrishvili, Laurent Managadze
Sep 4, 2012·European Urology·Siamak DaneshmandLori Wood
Sep 7, 2012·Urology·Philip KimSiamak Daneshmand
Nov 16, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BeyerC Wittekind
Feb 16, 2015·Clinical Genitourinary Cancer·Brian HuSiamak Daneshmand
Jul 29, 2015·The Urologic Clinics of North America·Thomas Kunit, Günter Janetschek
Feb 6, 2017·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·K Yadav
Mar 23, 2017·European Urology·Sumeet Syan-BhanvadiaSiamak Daneshmand
Citations
Jul 7, 2018·Current Opinion in Urology·Ryan P WerntzScott E Eggener
Jul 14, 2018·Current Opinion in Urology·Solomon L Woldu, Aditya Bagrodia
Dec 27, 2018·Current Opinion in Urology·Harsha R Mittakanti, James R Porter
Oct 17, 2021·World Journal of Urology·Muhannad Alsyouf, Siamak Daneshmand
Oct 27, 2021·Current Opinion in Urology·Muhannad Alsyouf, Siamak Daneshmand